Public Company Edition: Denali launched this year's largest biopharma IPO. Also, Valeant sold notes to retire older debt, while bluebird, Blueprint and others capitalized on data presented at ASH.
In an era of drug development in which everyone seems to be raising money for an immuno-oncology start-up, it's remarkable that the biggest initial public offering in the US by a biopharmaceutical company in 2017 was done by Denali Therapeutics Inc., which is focused on neurodegeneration.
Denali closed its IPO on Dec. 12 with the sale of nearly 16m shares at $18 each for gross proceeds...
Create an account to read this article
Already a subscriber?
Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.
Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.
Public Company Edition: Sarepta restructured after stopping shipments of its Elevidys for some patients to ease future debt pressures, but now it has stopped shipments to all patients. Also, Madrigal secured up to $500m in new debt, Cogent closed a $230m offering and other financings.
Looking to improve on the efficacy and safety of Roche’s Esbriet and BI’s Ofev, Avalyn has inhalable formulations of those drugs in Phase IIb and Phase I, respectively.
Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.
The Swiss giant has been talking to the US government about selling medicines directly to patients.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
